Purpose
To address the growing demand for novel therapies that target the underlying causes of cardiovascular disease (CVD), specifically the unmet need for treatments that prevent myocardial infarction (MI) and stroke.
Background
Atherosclerosis, a chronic inflammatory disease, remains a primary driver of heart attack and stroke. Despite strides in identifying risk factors and implementing tools like statins, cardiovascular deaths continue to rise globally. Notably, most cardiovascular events occur in patients with multiple risk factors who have not previously experienced an event—our focus is on this “forgotten majority.”
Research indicates that the inflammatory processes leading to plaque rupture and thrombosis are associated with certain bacterial pathogens, notably Porphyromonas gingivalis, found in atherosclerotic plaques. This insight is foundational to our work as we explore innovative methods to target these pathogens and reduce inflammation-driven cardiovascular events.
Approach
- Identifying intracellular pathogens in tissues from atherosclerosis patients.
- Setting up a high-throughput screening (HTS) system to test inhibitors of intracellular pathogens.
- Using in vitro systems to evaluate effective agents from drug and chemical libraries.
- Identifying novel antimicrobial drugs specific to intracellular pathogens.
- Validating efficacy in animal models, which have demonstrated a significant reduction in atherosclerotic plaques.
- Filing a provisional patent to protect our discoveries.
Unique Platform Technology
Our approach introduces a new, highly prevalent risk factor for cardiovascular disease—bacterial infection. We are among the first to pinpoint and target these pathogens within the immune system, marking a significant advance in the field.
- The target population includes not only patients with ischemic event histories but also the broader “forgotten majority.”
- Our systemic treatment addresses inflammation in CVD, with potential benefits across various cardiovascular sites.
- Repurposing FDA-approved drugs provides a fast track to therapy, while platform-specific discoveries are patent-protected.
- This platform technology also has applications in treating periodontal disease, arthritis, and other chronic inflammatory conditions.
Frequently Asked Question
What is the focus of Magnacor Therapeutics’ research?
Magnacor is dedicated to developing a novel class of drugs that target atherosclerosis and other chronic inflammatory diseases. Our research specifically addresses cardiovascular disease, aiming to provide therapies for patients with critical unmet medical needs.
What stage is Magnacor Therapeutics in its research and development process?
We have successfully completed animal trials that showed promising results in reducing atherosclerotic plaques. Currently, we are preparing for human trials to further test our therapies with the goal of bringing life-changing treatments to patients worldwide.
How is your approach to cardiovascular disease treatment different?
Our approach focuses on addressing bacterial pathogens associated with atherosclerotic plaques, a factor largely overlooked in traditional treatments. By targeting these intracellular pathogens, we aim to reduce inflammation and atherosclerotic plaque formation, providing a more comprehensive solution to cardiovascular disease.
How can I get involved with Magnacor Therapeutics’ mission?
We welcome interest from potential investors, collaborators, and partners who are passionate about advancing cardiovascular care. Reach out via our Contact Us page to explore opportunities for investment, licensing, or collaboration.